Author:
Esser Marc,Brunner Helmut
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference58 articles.
1. Hollingshead LM, Goa KL. Recombinant granulocyte-colony stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991 Aug; 42 (2): 300–30
2. Adams JR, Lyman GH, Djubegovic B, et al. G-CSF as prophy-laxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002; 3 (9): 1273–81
3. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998 Sep; 16 (9): 3179–90
4. Bennett CL, Smith TJ, Hillner BE, et al. Free-riding and prisoner’s dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995 Sep 13; 14 (9): 2457–63
5. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. J Clin Oncol 1996 Sep; (14): 2511–20
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献